To include your compound in the COVID-19 Resource Center, submit it here.

Aclasta regulatory update

FDA said that a review of data from nearly 40,000 patients in placebo-controlled trials of four marketed bisphosphonates showed

Read the full 199 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE